ORIGINAL RESEARCH article
Front. Pediatr.
Sec. Pediatric Hematology and Hematological Malignancies
This article is part of the Research TopicAdvances in the Diagnosis and Treatment of Pediatric Hematological DisordersView all articles
P2RX1 Promotes Mitochondrial Apoptosis via Calcium/CaM KII-Mediated Suppression of PI3K/Akt Signaling in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Provisionally accepted- 1First Affiliated Hospital of Harbin Medical University, Harbin, China
- 2Institute of Hematology and Oncology of Heilongjiang Province, Harbin, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Introduction: Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) continues to pose a major clinical challenge. Although tyrosine kinase inhibitor (TKIs)-based regimens form the cornerstone of therapy, treatment outcomes are compromised by difficulties in achieving remission, high relapse rates, and the critical issue of drug resistance. This study aims to elucidate the role of the purinergic receptor P2RX1 in the pathogenesis of and therapeutic response in Ph+ ALL. Methods: By analyzing P2RX1 expression levels in an online patient database and its association with prognosis, we evaluated the potential significance of this receptor in clinical outcomes. A P2RX1 overexpression model was established in the SUP-B15 Ph+ ALL cell line, and a series of functional experiments were conducted to assess its impact on tyrosine kinase inhibitor-induced apoptosis and proliferation capacity. To further elucidate its mechanism of action, we monitored changes in intracellular calcium ion concentration, mitochondrial membrane potential, and ATP production levels. Additionally, RT-PCR and Western blot analysis were employed to assess the activation status of the PI3K/Akt signaling pathway, CaMKII, and apoptosis-related proteins BAX, BAD, cytochrome C, and caspases Results: Analysis of the online patient database revealed that high expression of P2RX1 was significantly associated with poor clinical outcomes. Functional experiments demonstrated that overexpression of P2RX1 in SUP-B15 cells markedly enhanced their sensitivity to apoptosis induced by tyrosine kinase inhibitors; conversely, treatment with the CaMKII inhibitor KN-62 significantly suppressed cell proliferation. Mechanistically, excessive P2RX1 activation disrupts intracellular calcium homeostasis, leading to reduced mitochondrial membrane potential and ATP depletion, thereby activating the intrinsic apoptotic pathway. This process involves inhibition of the PI3K/Akt signaling pathway, hyperactivation of CaMKII, and upregulation of pro-apoptotic proteins such as BAX, Bad, cytochrome C, and cleaved caspase-3 and cleaved caspase-9. Conclusion: This study reveals the role of P2RX1 as a calcium-regulated tumor suppressor in Ph+ ALL, promoting apoptosis by disrupting mitochondrial function and inhibiting the PI3K/Akt survival signaling pathway, thereby providing a novel therapeutic approach to overcome TKI resistance.
Keywords: Ph+ALL1, P2RX12, CaM KII3, apoptosis4, PI3K/AKT5
Received: 22 Oct 2025; Accepted: 26 Nov 2025.
Copyright: © 2025 Li, Ren, Ye, Feng and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Lei guang Feng
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
